Stoke Therapeutics, STK-002, Autosomal Dominant Optic Atrophy, ADOA, OPA1 Gene, RNA Medicine, Antisense Oligonucleotide, ASO, OSPREY Study, FALCON Study,

BEDFORD, Massachusetts — October 12, 2026 Stoke Therapeutics announced new data supporting the potential disease-modifying activity of STK-002, an...